Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients' healthcare costs.

Ranjan, Tulika; Yu, Alexander; Elhamdani, Shaed; Howard, Candace M; Lirette, Seth T; Denning, Krista L; Valluri, Jagan; Claudio, Pier Paolo

Ranjan, Tulika; Yu, Alexander; Elhamdani, Shaed; Howard, Candace M; Lirette, Seth T; Denning, Krista L; Valluri, Jagan; Claudio, Pier Paolo.

Afiliação

Ranjan T; Department of Neuro-oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Yu A; Department of Neuro-Oncology, Cancer Center Southern Florida, and Tampa General Hospital, Tampa, Florida, USA.
Elhamdani S; Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Howard CM; Department of Neuro-oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Lirette ST; Department of Radiology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Denning KL; Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Valluri J; Department of Anatomy and Pathology, Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, USA.
Claudio PP; Translational Genomics Laboratory, Department of Biological Sciences, Marshall University, Huntington, West Virginia, USA.

Neurooncol Adv ; 5(1): vdad055, 2023.

Article em En | MEDLINE | ID: mdl-37287692

Palavras-chave

Cancer Stem Cell Assay; Cancer stem cells; ChemoID; Recurrent Glioblastoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Observational_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google